[ad_1]
Aware: 2021-02-20 07:51
Vladimir Ivanovo (VŽ) nuotr.
Pfizer and BioNTech have provided the US pharmaceutical regulator with new data showing that the COVID-19 vaccine developed by the companies can be stored at a much higher temperature than previously announced.
“The data provided can facilitate the handling of our vaccine in pharmacies and give vaccination centers even more flexibility,” said Ugur Sahin, CEO and co-founder of BioNTech.
The Pfizer and BioNTech vaccine is said to remain unchanged and is stored and transported between minus 15 and minus 25 degrees.
These doses of vaccine are currently stored in ultra-low temperature freezers with temperatures ranging from minus 60 to minus 80 degrees.
It has been announced that Pfizer and BioNTech can be stored for up to two weeks at elevated temperatures. Most conventional medical freezers can reach temperatures of minus 15 to minus 25 degrees.
On Friday, the authoritative medical journal The Lancet published an article in which it stated that the first dose of the COVID-19 vaccine, developed by the American pharmaceutical giant Pfizer and the German biotechnology company BioNTech, is 85% effective.
Canadian medical experts have proposed delaying vaccinations with the second dose of the vaccine, given the relatively strong immune response after the first injection, thus increasing the number of people vaccinated.
Write a comment
[ad_2]
